Compare Occidental Petroleum Corporation (OXY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Occidental Petroleum Corporation trades at $60.07 (market cap $58.19B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B). The key difference: Occidental Petroleum Corporation is far larger — about 25.2× Recursion Pharmaceuticals Inc's market cap, and Occidental Petroleum Corporation pays a 1.92% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| OXY | RXRX | |
|---|---|---|
Market Cap | $58.19B | $2.31B |
Volume | 7,092,290 | 40,478,768 |
Sector | Energy | Health |
52-Week High | $66.24 | $6.79 |
52-Week Low | $38.92 | $2.84 |
Typical Hold Time | 92 Days | 22 Days |
Enterprise Value | $76.95B | $1.83B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $60.28, up 3.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by a consensus price target of $71.40, indicating potential upside. Recent news highlights Goldman Sachs' upgrade to Buy, citing cash flow targets and debt reduction. Revenue has declined from $36.6B in 2022 to $21.6B in 2025, but net income margin remains healthy at 30.32%, and the company maintains a solid balance sheet with manageable debt levels.
OXY presents a favorable risk-reward profile with analyst optimism and operational efficiency, though exposure to oil price volatility and competitive pressures pose risks. The upcoming Q3 2026 earnings report on November 9 is a key catalyst. Institutional sentiment is positive, with 52% of analysts rating it Buy. Investors should weigh the stock's valuation appeal against macroeconomic headwinds affecting the energy sector.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
